Article

A rapid low-cost real-time PCR for the detection of Klebsiella pneumonia carbapenemase genes.

Department of Laboratory Medicine, Beijing Tongren Hospital, Capital Medical University, No1, Dongjiaominxiang Road, Dongcheng District, Beijing, 100730, China.
Annals of Clinical Microbiology and Antimicrobials (Impact Factor: 1.62). 04/2012; 11:9. DOI: 10.1186/1476-0711-11-9
Source: PubMed

ABSTRACT Klebsiella pneumonia carbapenemases (KPCs) are able to hydrolyze the carbapenems, which cause many bacteria resistance to multiple classes of antibiotics, so the rapid dissemination of KPCs is worrisome. Laboratory identification of KPCs-harboring clinical isolates would be a key to limit the spread of the bacteria. This study would evaluate a rapid low-cost real-time PCR assay to detect KPCs.
Real-time PCR assay based on SYBR GreenIwas designed to amplify a 106 bp product of the blaKPC gene from the 159 clinical Gram-negative isolates resistant to several classes of -lactam antibiotics through antimicrobial susceptibility testing. We confirmed the results of real-time PCR assay by the conventional PCR-sequencing. At the same time, KPCs of these clinical isolates were detected by the modified Hodge test (MHT). Then we compared the results of real-time PCR assay with those of MHT from the sensitivity and specificity. Moreover, we evaluated the sensitivity of the real-time PCR assay.
The sensitivity and specificity of the results of the real-time PCR assay compared with those of MHT was 29/29(100%) and 130/130(100%), respectively. The results of the real-time PCR and the MHT were strongly consistent (Exact Sig. (2-tailed) =1. 000; McNemar test). The real-time PCR detection limit was about 0.8 cfu using clinical isolates.
The real-time PCR assay could rapidly and accurately detect KPCs -harboring strains with high analytical sensitivity and specificity.

0 Bookmarks
 · 
139 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: This review describes recent findings related to molecular-based methods of potential application in the diagnosis of bacterial hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP). It focuses on methods capable of providing organism identification and keys of bacterial resistance necessary in clinical and epidemiological management of patients and on their ability to provide quantitative results. Significant advances have been made in recent years in the field of molecular diagnosis of bacterial pathogens. Real-time PCR, hybridization and mass spectrometry-based platforms dominate the scene. Some of the new technologies provide high sensitivity and specificity in the identification of single or multiple pathogens or a combination of etiological identification and antimicrobial resistance determinants in Staphylococcus aureus, nonfermenter Gram-negative bacilli and Enterobacteriaceae that are often associated with the cause of bacterial HAP/VAP in the late onset of the disease. In diagnosis made directly from clinical specimens and quantification of targets for bacterial load, some of them are promising. Despite some limitations, current molecular diagnostic methods have a great potential to include bacterial targets useful in the identification of microorganisms and antimicrobial resistance, to analyze directly unprocessed samples and to obtain quantitative results in bacterial HAP/VAP, an entity of complex microbiological diagnosis due to the features of the pathogens commonly implicated.
    Current opinion in critical care 08/2012; 18(5):487-94. · 2.67 Impact Factor

Full-text

View
5 Downloads
Available from